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Introduction and background
===========================

Transsphenoidal surgery (TSS) is a relatively safe and very effective approach for reaching parasellar and suprasellar tumors. Cerebral vasospasm is an extremely rare, life-threatening complication of TSS that can be difficult to diagnose because of its delayed presentation and heterogeneous course \[[@REF1]\]. The symptomatic onset of vasospasm typically occurs 5 to 10 days after surgery, mimicking the time course of vasospasm observed in the setting of aneurysmal subarachnoid hemorrhage (SAH) \[[@REF2]-[@REF4]\]. Clinically, vasospasm presents with signs and symptoms associated with ischemia in the territory of the implicated vessel(s).

Although the mechanism of post-TSS vasospasm is uncertain, postoperative SAH seems to be the most consistent risk factor. SAH has been observed in the majority of post-TSS vasospasm cases (84.6%) and is presumed to have a pathophysiological role, although vasospasm in the absence of SAH has been described \[[@REF5]-[@REF8]\]. Vasospasm is thought to be an infrequent contributor to the overall spectrum of ischemic complications after TSS, which includes direct injury to the internal carotid artery (ICA) and compression secondary to apoplexy \[[@REF9]\]. However, the treatment of this idiosyncratic condition lacks evidence-based guidelines, and even with intensive care, the mortality rate associated with post-TSS vasospasm is approximately 30% \[[@REF4],[@REF5],[@REF10]\].

Compared to the typical complications of pituitary tumor resection (e.g., diabetes insipidus \[DI\], pituitary insufficiency, cerebrospinal fluid \[CSF\] leak, meningitis, vision deficits), reports of symptomatic vasospasm after TSS are sparse \[[@REF1],[@REF4]-[@REF6],[@REF9],[@REF11]-[@REF19]\]. As a consequence, very little is understood about the prevalence, etiology, and management of this condition. We report here our experience with two cases of symptomatic vasospasm and delayed cerebral ischemia after endoscopic TSS for resection of a tuberculum sella meningioma (case 1) and a pituitary adenoma (case 2). We also summarize our review of published cases to highlight the common presenting features, timing, clinical course, and management strategies.

Review
======

Institutional miniseries

During the year of 2019, two patients who underwent endoscopic TSS for pituitary tumor resection at the Indiana University Department of Neurological Surgery developed symptomatic vasospasm within two weeks of surgery. The medical records for these patients were accessed retrospectively, and the following clinical variables were extracted from each patient's chart: demographics (age and sex), presenting symptoms, tumor extension, histopathological diagnosis, the documented occurrence of CSF leak, identification of postoperative SAH, postoperative DI, postoperative day (POD) of vasospasm diagnosis, clinical signs and symptoms during vasospasm, diagnostic modality used to confirm vasospasm, the vessels involved, management strategy, and outcome at discharge or last follow-up.

Institutional review board/ethics committee approval and patient consent were neither required nor sought for this study.

Literature review

We searched the literature for all published cases of symptomatic vasospasm after TSS for sellar or suprasellar tumor resection. An initial set of articles was obtained by querying the Medline/PubMed database with the following search terms (similar to those used by Mansouri et al.): \["pituitary"\] and \["vasospasm" or "spasm" or "delayed cerebral ischemia"\] and \["resection" or "surgery" or "transsphenoidal" or "TSS" or "ETSS"\] \[[@REF4]\]. Additional articles were obtained by cross-checking references and hand searching in Medline/PubMed and Google Scholar. Articles published in a language other than English were discarded. Cases in which vasospasm was preceded by pituitary apoplexy were also excluded because of the established risk of cerebral vasospasm in patients with this disorder \[[@REF4]\]. The literature search was performed by two independent authors (H.C.B. and S.B.T.), and inconsistencies were resolved by discussion with the senior author (A.C.G.). After screening each abstract for relevance, full-length articles were reviewed for the clinical variables listed earlier.

Statistical reporting

Descriptive statistics (means and standard deviations) are used to report group-level continuous data from the literature search. Categorical variables (e.g., presence of SAH) were reported as percentages. Variables that could not be readily categorized (e.g., symptoms during vasospasm) are presented individually.

Case 1

A 36-year-old right-handed woman presented with a mild right homonymous hemianopsia. MRI revealed a large suprasellar mass with prepontine cisternal extension, encasement of the left proximal posterior cerebral artery (PCA), and partial encasement of the bilateral supraclinoid ICA and A1 segments (Figure [1A](#FIG1){ref-type="fig"}). She underwent endoscopic TSS, which resulted in a gross-total resection of a large tuberculum sella meningioma. A lumbar drain was used during the surgery for CSF drainage and continued postoperatively. The optic nerves were decompressed during the operation, but no significant dissection of the nerves was required. Allograft was used for closure. No obvious CSF leak or excessive bleeding was noted during the operation.

![Case 1: 36-year-old woman\
Preoperative contrast-enhanced T1-weighted MRI reveals a large suprasellar mass with prepontine cisternal extension, encasement of the left proximal PCA, and partial encasement of bilateral supraclinoid ICA and A1 segments (arrow). (B) CT of the head shows IVH within the fourth ventricle on POD 0 (arrow). (C) CTA of the head on POD 16 suggests delayed cerebral vasospasm in the ACA and MCA territories (asterisks), worse on the left than the right side. (D) Vasospasm is also apparent in the PCA territory (asterisks), worse on the left side. (E) Digital subtraction angiography reveals severe vasospasm in the left paraclinoid ICA (arrow). (F) Left PCA infarct (DWI, then ADC) (arrows). (G) Bilateral ACA infarcts (DWI, then ADC) (arrows)\
CTA, CT angiography; PCA, posterior cerebral artery; ICA, internal carotid artery; IVH, intraventricular haemorrhage; ACA, anterior cerebral artery; MCA, middle cerebral artery; DWI, diffusion-weighted imaging; ADC, apparent diffusion coefficient; POD; postoperative day](cureus-0012-00000008171-i01){#FIG1}

Shortly after surgery, the patient developed DI and a significant worsening of her vision. CT of her head revealed intraventricular hemorrhage (IVH) within the fourth ventricle, which prompted the initiation of dexamethasone (Figure [1B](#FIG1){ref-type="fig"}). On POD 3, she developed a nasal CSF leak, which was treated with CSF diversion via the lumbar drain. Her DI and pain remained difficult to manage, but her vision began to improve. The lumbar drain was discontinued, and she was transferred out of the intensive care unit (ICU) on POD 6. On POD 7, she was transferred back to the ICU for correction of severe hyponatremia (sodium level, 116 mEq/L) with intravenous hypertonic saline, oral salt replacement, and fludrocortisone.

On POD 13, the patient developed acute dysarthria, anxiety, right-arm apraxia, and gait instability, which spontaneously resolved over several hours. On POD 16, she had altered mental status and right hemiparesis, which prompted emergent imaging. CT of her head revealed an acute infarct of the left frontal lobe. CT angiography (CTA) of her head suggested delayed cerebral vasospasm (Figure [1C](#FIG1){ref-type="fig"} and D). Digital subtraction angiography revealed severe vasospasm in the paraclinoid left ICA, which resolved with balloon angioplasty, and mild-to-moderate left A1 and proximal left M2 vasospasm, which required super-selective intra-arterial papaverine administration (Figure [1E](#FIG1){ref-type="fig"}). Therapeutic hypertension (systolic blood pressure goal, \>180 mm Hg) was initiated. Nimodipine was avoided because of the difficulty maintaining therapeutic hypertension. MRI revealed acute infarcts of the bilateral anterior cerebral artery (ACA) and left middle cerebral artery (MCA) distributions (Figures [1F](#FIG1){ref-type="fig"} and G). Transcranial Doppler (TCD) ultrasonography continued to reveal evidence for MCA vasospasm on POD 17, which prompted the initiation of vasopressors. Over the next week, she remained in the ICU and underwent daily monitoring with TCD ultrasonography. By POD 27, the patient had regained full strength and returned to her cognitive baseline. At discharge, her only lasting deficits were right-hand clumsiness and preexisting visual field deficits.

Case 2

A 55-year-old man presented with a three-month history of vision loss, erectile dysfunction, and diminished libido. MRI revealed a pituitary adenoma (Figure [2A](#FIG2){ref-type="fig"}). He underwent endoscopic TSS, which was complicated by an intraoperative CSF leak. His preoperative lumbar drain was left in place after surgery for CSF diversion. The patient developed DI on POD 1, and CT of his head performed at this time revealed SAH in the basal cisterns (Figure [2B](#FIG2){ref-type="fig"}). He was started on prophylactic therapy with intravenous fluids, nimodipine, levetiracetam, and atorvastatin.

![Case 2: 55-year-old man\
(A) Pituitary adenoma on preoperative MRI (asterisks). (B) CT of the head performed on POD 1 reveals SAH in the basal cisterns (arrow). (C) On POD 12, CTA of the head confirms vasospasm in the right MCA (asterisk). (D) Cerebral angiography performed on POD 14 reveals severe right ACA vasospasm (arrow), which was subsequently treated with intra-arterial nicardipine\
POD, postoperative day; CTA, CT angiography; MCA, middle cerebral artery; ACA, anterior cerebral artery](cureus-0012-00000008171-i02){#FIG2}

On POD 7, the patient developed altered mental status and acute lethargy. TCD ultrasonography results were consistent with bilateral MCA vasospasm. Therapeutic hypertension was initiated with a systolic blood pressure goal of \>180 mm Hg. His clinical course fluctuated over the next few days in accordance with his hemodynamic status. On POD 12, CTA of his head confirmed vasospasm in the bilateral supraclinoid ICAs, MCAs, and A1 segments (Figure [2C](#FIG2){ref-type="fig"}). On POD 14, the patient was brought to the interventional radiology suite for intra-arterial nicardipine administration (Figure [2D](#FIG2){ref-type="fig"}). After endovascular treatment, no evidence of clinical or subclinical vasospasm was found, and the patient was weaned off of intravenous fluids. TCD ultrasonography results gradually normalized, and the patient was discharged from the hospital on POD 21 without any deficits. 

Literature review results

Including our two institutional cases, our literature search identified 21 articles describing 34 cases of TSS complicated by symptomatic vasospasm (Table [1](#TAB1){ref-type="table"}). Of these cases, 13 (38.2%) overlap with the recent literature review performed by Eseonu et al., whereas the remaining cases, to our knowledge, have not been presented in this format \[[@REF5]\]. Female patients accounted for 58.8% of the patients in these cases, and the overall mean age at the time of surgery was 48.1 ± 12.9 years (range, 19-74 years). Common presenting signs and symptoms before surgery included headache, fatigue, visual disturbance, amenorrhea, sexual dysfunction, and hypopituitarism. The most prevalent pathologies were pituitary adenoma (70.6%) and craniopharyngioma (11.8%).

###### Reported cases of symptomatic post-TSS vasospasm: clinical characteristics

ACA, anterior cerebral artery; CN, cranial nerve; CSF, cerebrospinal fluid; CTA, computed tomography angiogram; DI, diabetes insipidus; DSA, digital subtraction angiography; EBL, estimated blood loss; F, female; GOS, Glasgow Outcomes Scale; IA, intra-arterial; IVH, intraventricular hemorrhage; M, male; MRA, magnetic resonance angiography; NR, not reported; POD, postoperative day; SAH, subarachnoid hemorrhage; TCD, transcranial Doppler ultrasonography; triple H, hemodilution, hypertension, and hypervolemia; TSS, transsphenoidal surgery

  ---------------------------------- --------- ---------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------ ------------------------------------------------------ ------------------------------- --------------------------------------------- -------------------------------- ------------------------------------------------------------- ---------------------------------------------------------------------------- -----------------------------------------------------------
  Case                               Age (y)   Sex                                                              Presenting symptom(s)                                Tumor type                                 Tumor extension                                        CSF leak                        SAH/postop hemorrhage                         Vasospasm (POD)                  Diagnostic modality                                           Management                                                                   Outcome
  Camp et al et al. \[[@REF20]\]     33        F                                                                Amenorrhea, galactorrhea                             Pituitary adenoma                          Large sellar                                           Yes                             No                                            6                                Cerebral angiography                                          Triple H, antibiotics                                                        Death
  Hyde-Rowan et al. \[[@REF21]\]     30        F                                                                Galactorrhea, headache, blurred vision               Pituitary adenoma                          NR                                                     No                              Yes (1.4 L EBL, SAH on POD 2)                 5                                Cerebral angiography                                          Conservative                                                                 Death
  Cervoni et al. \[[@REF22]\]        51        M                                                                NR                                                   Pituitary adenoma                          Suprasellar                                            NR                              Yes (SAH, POD 4)                              NR                               TCD                                                           Triple H, nimodipine                                                         Complete recovery
  Friedman et al. \[[@REF23]\]       41        M                                                                Acromegaly                                           Pituitary adenoma                          NR                                                     No                              No                                            10                               Cerebral angiography                                          Balloon angioplasty                                                          Complete recovery
  Nishioka et al. \[[@REF24]\]       41        M                                                                Decreased libido, vision changes                     Pituitary adenoma                          Suprasellar                                            No                              Yes                                           12                               Cerebral angiography                                          IA papaverine, triple H, thromboxane A2 antagonist                           Stable hypopituitarism
  Kasliwal et al. \[[@REF14]\]       34        F                                                                Amenorrhea, galactorrhea, headache, vision changes   Pituitary adenoma                          Suprasellar                                            Yes                             Yes (hematoma)                                13                               Cerebral angiography, TCD                                     Hypervolemia                                                                 Death
  Popugaev et al. \[[@REF25]\]       45        M                                                                NR                                                   Pituitary adenoma                          Suprasellar                                            Yes                             Yes (SAH on POD 4)                            4                                TCD, cerebral angiography                                     IV antibiotics                                                               GOS 4
  52                                 F         NR                                                               Pituitary adenoma                                    Suprasellar                                NR                                                     No                              4                                             TCD                              IV antibiotics                                                GOS 5                                                                        
  Zada et al. \[[@REF13]\]           59        M                                                                Bitemporal hemianopsia, hypogonadism                 Pituitary adenoma                          Suprasellar, floor of third ventricle, encasing ACAs   NR                              Yes (SAH and hematoma on POD 2)               2                                Cerebral angiography, CTA                                     IA verapamil (3×)                                                            Short-term memory and stable visual field deficits
  66                                 M         Visual blurring, hypogonadism                                    Pituitary adenoma                                    Suprasellar, right frontal lobe invasion   NR                                                     Yes (hematoma on POD 5)         8                                             Cerebral angiography, MRA        IA verapamil                                                  Death                                                                        
  36                                 F         Headache, vision change, hypopituitarism                         Pituitary adenoma                                    Suprasellar                                NR                                                     Yes (SAH on POD 0)              9                                             CTA                              Triple H, IA verapamil (4×)                                   Stable hypopituitarism                                                       
  Puri et al. \[[@REF1]\]            59        M                                                                NR                                                   Pituitary adenoma                          Suprasellar, floor of third ventricle                  No                              Yes                                           5                                Cerebral angiography                                          IA verapamil, triple H, nimodipine                                           Cognitive and visual deficits, mild weakness
  36                                 F         Vision changes                                                   Pituitary adenoma                                    Suprasellar                                No                                                     Yes                             9                                             CTA                              IA papaverine, triple H, nimodipine                           Stable hypopituitarism                                                       
  66                                 M         Headaches, hypogonadism                                          Pituitary adenoma                                    Suprasellar, right frontal lobe invasion   Yes                                                    Yes                             8                                             Cerebral angiography             Triple H, nimodipine, IA verapamil                            Death                                                                        
  Kim et al. \[[@REF11]\]            51        M                                                                Vision changes                                       Pituitary adenoma                          Suprasellar                                            No                              Yes                                           9                                Cerebral angiography                                          Triple H, nimodipine                                                         Complete recovery
  74                                 M         Vision changes, headaches                                        Pituitary adenoma                                    Suprasellar                                No                                                     Yes                             9                                             Cerebral angiography             IA papaverine, triple H, nimodipine                           Complete recovery                                                            
  65                                 F         Vision changes                                                   Pituitary adenoma                                    Suprasellar                                No                                                     Yes                             7                                             Cerebral angiography             IA papaverine, triple H, nimodipine                           Minor residual weakness                                                      
  51                                 F         Vision changes                                                   Pituitary adenoma                                    Suprasellar                                No                                                     Yes                             9                                             Cerebral angiography             IA papaverine, triple H, nimodipine                           Complete recovery                                                            
  Page et al. \[[@REF8]\]            44        F                                                                Headaches, vision changes, nausea                    Pituitary adenoma                          Suprasellar                                            No                              No                                            3                                TCD, CTA                                                      Nimodipine, triple H                                                         Tracheostomy, gastrostomy, long-term rehabilitation
  Eseonu et al. \[[@REF5]\]          43        F                                                                Headache, fatigue, vision changes                    Pituitary adenoma                          Suprasellar                                            Yes                             Yes (tumor bed hemorrhage)                    12                               MRA, TCD                                                      Hypertension, euvolemia, phenylephrine, nimodipine                           Complete recovery
  Nash et al. \[[@REF18]\]           48        F                                                                NR                                                   Craniopharyngioma                          NR                                                     No                              No                                            11                               MRI, MRA                                                      Hypertension, nimodipine                                                     Complete recovery
  49                                 F         Vision changes                                                   Craniopharyngioma                                    NR                                         No                                                     No                              5                                             CTA, cerebral angiography        Hypertension, hypervolemia, balloon angioplasty, nimodipine   Mild residual dysphagia                                                      
  Bierer et al. \[[@REF17]\]         54        M                                                                Vision changes                                       Meningioma                                 Suprasellar                                            Yes                             No                                            11                               MRA                                                           Antibiotics                                                                  Subtle personality changes and impaired short-term memory
  Bougaci and Paquis \[[@REF15]\]    60        M                                                                Vision changes, hypopituitarism                      Pituitary adenoma                          Suprasellar, bilateral cavernous sinuses               No                              Yes (SAH and suprasellar hematoma on POD 0)   9                                Cerebral angiography                                          Balloon angioplasty                                                          Complete recovery
  Osterhage et al. \[[@REF9]\]       52        M                                                                Homonymous hemianopsia                               Pituitary adenoma                          Suprasellar                                            No                              Yes (SAH)                                     8                                Cerebral angiography, TCD, CTA                                IA nimodipine                                                                Complete recovery
  55                                 F         Headaches, DI                                                    Rathke\'s cyst                                       Suprasellar                                No                                                     Yes (prepontine)                13                                            Cerebral angiography, TCD, CTA   IA nimodipine, aspirin                                        Impaired left hand motor skills, CN III palsy, hypopituitarism               
  42                                 F         Headaches, dizziness, DI                                         Rathke cleft cyst/ granulation tissue                NR                                         No                                                     Yes (hematoma \[prepontine\])   12                                            Cerebral angiography, TCD, CTA   IA nimodipine                                                 Complete recovery                                                            
  56                                 F         Hydrocephalus, chiasmal syndrome, gait and speech disturbances   Craniopharyngioma                                    Suprasellar                                Yes                                                    Yes (SAH, IVH)                  2                                             Cerebral angiography, TCD, CTA   IA nimodipine                                                 Death                                                                        
  Suero Molina et al. \[[@REF16]\]   23        F                                                                Hypopituitarism                                      Pituitary adenoma                          Suprasellar                                            Yes                             Yes                                           8                                Cerebral angiography, CTA                                     IA and IV nimodipine, hypertension                                           Slight facial droop
  Karimnejad et al. \[[@REF2]\]      19        F                                                                Headache, nausea, vomiting, fatigue, vision change   Lymphocytic hypophysitis                   Suprasellar                                            No                              No                                            9                                MRI, MRA                                                      Nimodipine, triple H, IA nicardipine                                         Global aphasia, right hemiplegia
  Ricarte et al. \[[@REF6]\]         67        F                                                                NR                                                   Craniopharyngioma                          Suprasellar                                            NR                              No                                            16                               TCD, CTA                                                      Nimodipine, hypertension                                                     Mild paresis
  Aggarwal et al. \[[@REF7]\]        41        F                                                                Headache, amenorrhea, vision change                  Craniopharyngioma                          Suprasellar                                            NR                              No                                            9                                DSA, CTA                                                      IA milrinone, systemic milrinone                                             Complete recovery
  Current study                      36        F                                                                Right-sided visual field cut                         Tuberculum sella meningioma                Pre-pontine cistern                                    Yes                             Yes                                           16                               Cerebral angiography, CTA                                     Hypertension, hypervolemia, nimodipine, IA papaverine, balloon angioplasty   Slow gait and right-hand clumsiness
  55                                 M         Vision changes, sexual dysfunction                               Pituitary adenoma                                    Sellar                                     Yes                                                    Yes                             7                                             TCD                              IA nicardipine                                                Complete recovery                                                            
  ---------------------------------- --------- ---------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------ ------------------------------------------------------ ------------------------------- --------------------------------------------- -------------------------------- ------------------------------------------------------------- ---------------------------------------------------------------------------- -----------------------------------------------------------

The majority of patients exhibited postoperative SAH or intracranial hematoma (70.6%). The timing of postoperative SAH was not consistently documented among these reports. CSF leak (29.4%) and postoperative DI (17.6%) were reported less commonly, although they were observed in both of the patients treated at our institution.

The average onset of symptomatic vasospasm was POD 8.5 ± 3.6 (range, POD 2-16). The clinical presentation of vasospasm was extremely variable across patients, with many patients exhibiting some combination of altered mental status, lethargy, and/or focal neurological deficits referable to the territory of the compromised vessel(s) (Table [1](#TAB1){ref-type="table"}). Imaging modalities used to diagnose vasospasm included digital subtraction angiography (DSA), CTA, MRI/MRA, and TCD ultrasonography. In many patients, multiple modalities were used to confirm the diagnosis, identify the implicated vessels, and monitor for resolution or recurrence. DSA was often performed for both diagnostic and interventional purposes (see below).

The vessel(s) involved at the initial diagnosis of vasospasm was discerned in 94.1% of the cases; vasospasm in the remaining cases was described as "diffuse" \[[@REF13],[@REF25]\]. The majority of patients exhibited vasospasm in multiple cerebral vessels, usually involving the anterior circulation (Table [2](#TAB2){ref-type="table"}). In 40.6% of the patients, vasospasm was identified in segments of the ICA, MCA, and ACA simultaneously. The ACA was the most frequently implicated vessel, exhibiting spasm in 78.1%, with most cases involving the proximal segment. The supraclinoid segment was involved most frequently in patients with spasm of the ICA. The basilar arteries (12.5%), PCA (6.3%), and posterior communicating artery (3.1%) were rarely involved.

###### Vessels implicated in symptomatic vasospasm

ACA, anterior cerebral artery; ICA, internal carotid artery; MCA, middle cerebral artery; PCA, posterior cerebral artery; PComm, posterior communicating artery

  ---------------------------------- --------- ----- ----- ----- ------- ---------
  Study                              ICA       MCA   ACA   PCA   PComm   Basilar
  Current study                      X         X     X                    
  Current study                      X         X     X                    
  Aggarwal et al. \[[@REF7]\]        X         X     X                    
  Zada et al. \[[@REF13]\]           X         X     X                    
  Puri et al. \[[@REF1]\]            X         X     X                    
  Puri et al. \[[@REF1]\]            X         X     X                    
  Puri et al. \[[@REF1]\]            X         X     X                    
  Nishioka et al. \[[@REF24]\]       X         X     X                    
  Kim et al. \[[@REF11]\]            X         X     X                    
  Nash et al. \[[@REF18]\]           X         X     X                    
  Bougaci and Paquis \[[@REF15]\]    X         X     X                    
  Osterhage et al. \[[@REF9]\]       X         X     X                    
  Suero Molina et al. \[[@REF16]\]   X         X     X                    
  Karimnejad et al. \[[@REF2]\]      X         X     X                    
  Hyde-Rowan et al. \[[@REF21]\]     X                                    
  Friedman et al. \[[@REF23]\]       X                                    
  Kasliwal et al. \[[@REF14]\]       X                                    
  Eseonu et al. \[[@REF5]\]          X                                    
  Popugaev et al. \[[@REF25]\]                 X                          
  Osterhage et al. \[[@REF9]\]                 X                          
  Cervoni et al. \[[@REF22]\]                  X     X                    
  Page et al. \[[@REF8]\]                      X     X                    
  Nash et al. \[[@REF18]\]                     X     X                    
  Ricarte et al. \[[@REF6]\]                   X     X                    
  Bierer et al. \[[@REF17]\]                   X     X                   X
  Osterhage et al. \[[@REF9]\]                 X     X     X             X
  Zada et al. \[[@REF13]\]                           X     X              
  Kim et al. \[[@REF11]\]                            X                    
  Kim et al. \[[@REF11]\]                            X                    
  Kim et al. \[[@REF11]\]                            X                    
  Camp et al. \[[@REF20]\]           X                           X        
  Osterhage et al. \[[@REF9]\]       X               X                   X
  Popugaev et al. \[[@REF25]\]       Diffuse                             
  Zada et al. \[[@REF13]\]           Diffuse                             
  ---------------------------------- --------- ----- ----- ----- ------- ---------

A variety of treatment strategies were described in the literature (see Table [1](#TAB1){ref-type="table"}). Hemodynamic augmentation with hemodilution, hypertension, and hypervolemia (triple-H therapy) was very common but not universal among the cases. In patients who underwent intra-arterial therapy, the most frequently used agents were papaverine, verapamil, nimodipine, and milrinone. It was notable that 14.7% of the patients underwent endovascular balloon angioplasty. Systemic antibiotics were used in two cases for which post-TSS meningitis (not SAH) was the presumed cause of vasospasm \[[@REF25]\].

In terms of outcomes, death of the patient was reported in six (17.6%) cases. At the other extreme, for 41.2% of the patients, complete resolution, a Glasgow Outcome Scale score of 5, or no deficits were reported. Common deficits included residual extremity weakness (17.6%), pituitary insufficiency (8.8%), and cognitive deficits such as aphasia and memory impairment (8.8%). We found no consistency in the follow-up durations or outcome variables documented among the studies.

Discussion

Symptomatic vasospasm is a potentially deadly complication of TSS. The first reported case of angiogram-confirmed vasospasm after TSS emerged in 1980, and only a handful of cases have been reported in the years since then \[[@REF20]\]. In this study, we add two cases recently encountered at our institution to the literature, which now includes (to the best of our knowledge) a total of 34 cases.

Prevalence of symptomatic vasospasm after TSS

Rates of post-TSS vasospasm are unknown, but existing evidence suggests that the phenomenon is extremely rare. In the most compelling study on this topic, Osterhage et al. retrospectively examined just under 2,000 consecutive microscopic TSS cases treated at their center over an eight-year period \[[@REF9]\]. They identified symptomatic vasospasm as a postoperative complication in only four (0.2%) patients, two with a Rathke cleft cyst, one with a suprasellar craniopharyngioma, and one with a giant nonfunctioning pituitary adenoma. In all four cases, SAH preceded the onset of vasospasm. Despite the rigor and size of this retrospective analysis, the possibility that a certain number of vasospasm cases went undetected should be considered when interpreting their observed prevalence.

SAH is the major risk factor for symptomatic post-TSS vasospasm

Authors of the most recent literature review of post-TSS cerebral vasospasm evaluated 13 cases and found that SAH preceded the onset of symptomatic vasospasm in the majority (84.6%) of the patients \[[@REF5]\]. The results of this study and others suggest a prominent role of subarachnoid blood in triggering a vasospastic response. In its own right, significant SAH is a rare complication of TSS that occurs in just 1% to 2% of cases \[[@REF9],[@REF26]\]. There are limited data by which to ascertain how often SAH leads to the even rarer phenomenon of symptomatic vasospasm. However, Kim et al. found that 26.7% of patients who developed post-TSS SAH went on to exhibit angiogram-confirmed symptomatic vasospasm \[[@REF11]\]. 

The pathophysiology of post-TSS vasospasm remains uncertain. Many authors have drawn mechanistic parallels to the more common occurrence of vasospasm after aneurysmal SAH. In this setting, vasospasm is frequently attributed to the effects of blood breakdown products \[[@REF27]\]. Delayed vasospasm after open tumor resection has also been documented, especially after skull base tumor resection \[[@REF28],[@REF29]\]. The etiology of this complication has not been elucidated, but studies have identified sphenoid wing tumor location, a diagnosis of meningioma, postoperative bacterial meningitis, and SAH as risk factors \[[@REF10]\]. Manipulation of vessels during tumor resection is more common and more traumatic when the tumor encases the vessels, and as such, vascular encasement is a proposed risk factor for vasospasm \[[@REF30],[@REF31]\]. Vascular tone alteration via vessel manipulation during tumor resection has also been proposed as a mechanism for postoperative vasospasm via the impairment of vasodilation \[[@REF32]\]. Tumors have also been known to release vasogenic molecules such as calcium and lipids, which can induce vasospasm \[[@REF32],[@REF33]\].

Sellar tumors confer a larger risk of postoperative vasospasm because of their spatial relationship to the circle of Willis. In addition to the proposed etiologies of vasospasm after tumor resection, hypothalamic injury or electrolyte disturbance can contribute to the risk of vasospasm after TSS \[[@REF1],[@REF5],[@REF10],[@REF34]\]. Other proposed risk factors for postresection vasospasm are pituitary apoplexy, intraoperative CSF leak, basal cistern tumor extension, hyponatremia, and postoperative syndrome of inappropriate antidiuretic hormone \[[@REF35]\]. Hypothalamic dysfunction can also induce vasospasm by triggering a sympathetic discharge and catecholamine release \[[@REF36],[@REF37]\]. DI and the resultant electrolyte disruptions can also make a patient more susceptible to vasospasm \[[@REF38]\]. During craniopharyngioma or dermoid cyst resection, vasospasm can be caused by cystic fluid spillage, as seen in practice \[[@REF39]\] and in in vivo rat studies, in which cystic fluid injected into rats resulted in femoral artery vasospasm \[[@REF40]\]. In our cases, early mild vasospasm most likely led to intractable DI because of the resultant ischemia of the pituitary stalk and adjacent neurovascular structures.

Surveillance and treatment strategies for post-TSS vasospasm vary

It has been proposed that treatment for vasospasm after TSS should be similar to that for vasospasm after aneurysmal SAH, which includes euvolemia/hypervolemia, permissive hypertension, prevention of hyponatremia, seizure prevention, and endovascular treatment, if necessary \[[@REF3]\]. Given that this condition is relatively uncommon after tumor resection, especially transsphenoidal resection, systematic screening and treatment protocols have not been established at most institutions, including our own. Our literature review found an impressive heterogeneity of treatment strategies, including hemodynamic augmentation, systemic pharmacotherapy, intra-arterial antispasmodic medications/vasodilation, and angioplasty. There is a similar paucity of literature surrounding the issue of postoperative surveillance. Considering the potentially devastating consequences of undetected vasospasm, the index of suspicion should always remain high in the setting of acute neurologic deterioration in the face of an unchanged or nondiagnostic CT scan. Further complicating this matter is the assumption that neurologic deterioration caused by an expanding hematoma or syndrome of the inappropriate antidiuretic hormone could be treated with stricter blood pressure parameters and volume restriction, which can exacerbate vasospasm. This exacerbation can be a significant factor in poor final outcomes and should be strongly avoided.

Death is common in the setting of post-TSS vasospasm

Given the limitations of our retrospective literature review, we were unable to perform a rigorous examination of clinical outcomes over a consistent follow-up period with standardized outcome variables. However, the results of our review corroborate previous findings that suggested that death frequently occurs in the setting of post-TSS vasospasm \[[@REF4],[@REF5],[@REF10]\]. The mortality rate observed in our analysis (17.6%) is lower than the 30.8% mortality rate documented in the review by Eseonu et al. \[[@REF5]\]. There seems to be a temporal pattern in the reported deaths within our review; five of six cases involving death were published before 2013. Several non-mutually exclusive explanations might contribute to this pattern, including (1) increased awareness of this rare complication; (2) superior diagnostic capabilities, surveillance, and treatment options; and (3) changes in publishing trends, resulting in fewer accounts of unfavorable outcomes.

Conclusions
===========

Symptomatic vasospasm is a rare complication of transsphenoidal tumor resection. We evaluated a total of 34 reported cases to better understand the time course, presentation, treatment approaches, and outcomes of post-TSS vasospasm. Our results confirm that there is very limited evidence in the literature with which to make clinical decisions, leading to significant institutional or case-by-case heterogeneity. Despite intensive care, high morbidity and mortality rates are relatively common in the setting of this poorly understood complication.
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